Biote Q1 revenue falls

biote

06/05/2026 21:47

Overview

US hormone therapy provider's Q1 revenue fell 8.3% yr/yr, missing analyst expectations

Adjusted EBITDA dropped 37% yr/yr amid lower sales and higher costs

Company says voluntary recall and supply constraints hurt procedure revenue and gross margin

Outlook

Biote sees 2026 revenue above $190 mln

Company expects 2026 Adjusted EBITDA above $38 mln

Procedure revenue expected to return to growth in second half of 2026

Result Drivers

PRODUCT RECALL AND SUPPLY CONSTRAINTS - Co said voluntary recall of certain hormone pellet products and related supply constraints reduced procedure revenue and gross margin

HIGHER REPLACEMENT COSTS - Sourcing replacement products from third-party suppliers at higher costs and reduced manufacturing efficiencies lowered gross profit margin

DIETARY SUPPLEMENTS GROWTH - Dietary supplements revenue grew 19.1%, partially offsetting decline in procedure revenue

Company press release: ID:nBw26240Ka

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$44.90 mln
$46.02 mln (5 Analysts)
Q1 Adjusted EBITDA
$8.70 mln
Q1 Gross Margin
68.90%
Q1 Adjusted EBITDA Margin
19.40%
Q1 Operating Income
$3.20 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the professional information services peer group is "buy"

Wall Street's median 12-month price target for Biote Corp is $3.00, about 35.7% above its May 5 closing price of $2.21

The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 5 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)